All In Biotech

Drug Trial Radar · NCT07373613

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Feb 1, 2027

Study completion Feb 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

  • BR1400-1Drug

    One tablet administered alone

  • BR1400-2Drug

    One tablet administered alone

  • BR1400-3Drug

    One tablet administered alone

  • BR1400-4Drug

    One tablet administered alone

  • BR1400-5Drug

    One tablet administered alone

  • BR1400-ADrug

    One tablet administered alone

  • BR1400-BDrug

    One tablet administered alone

  • BR1400-CDrug

    One tablet administered alone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to treatment of 8 weeks in MSSBPTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hanyang University Hospital

    Soeul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.